TN2013000435A1 - Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process - Google Patents

Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process

Info

Publication number
TN2013000435A1
TN2013000435A1 TNP2013000435A TN2013000435A TN2013000435A1 TN 2013000435 A1 TN2013000435 A1 TN 2013000435A1 TN P2013000435 A TNP2013000435 A TN P2013000435A TN 2013000435 A TN2013000435 A TN 2013000435A TN 2013000435 A1 TN2013000435 A1 TN 2013000435A1
Authority
TN
Tunisia
Prior art keywords
prophylaxis
treatment
compounds
pharmaceutical compositions
vii
Prior art date
Application number
TNP2013000435A
Other languages
French (fr)
Inventor
Mikhail Gennadievich Shurygin
Irina Aleksandrovna Shurygina
Original Assignee
Pharmasyntez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2012/052483 external-priority patent/WO2012156938A1/en
Application filed by Pharmasyntez filed Critical Pharmasyntez
Publication of TN2013000435A1 publication Critical patent/TN2013000435A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the field of pharmacy, clinical and experimental medicine and veterinary medicine, and in particular to novel inhibitory compounds of a p38 MAP kinase with a structure of the type (I)-(VII) which can be used for the treatment or prophylaxis of adhesion. The invention discloses pharmaceutical compositions containing an effective amount of the substance SB203580 or one of the compounds of the type (I)-(VII) or a combination thereof and a pharmaceutically acceptable carrier, a diluent or an excipient. Also disclosed is the use of the substance SB203580 as an agent having anti-adhesion activity. Also disclosed is: a method for the prophylaxis and/or treatment of a disease or a condition in which there is the possibility of the formation and/or growth of adhesions which makes it possible to dispense with the additional administration of a preparation in the post-operative period.
TNP2013000435A 2011-12-26 2013-10-24 Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process TN2013000435A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2011153043 2011-12-26
PCT/IB2012/052483 WO2012156938A1 (en) 2011-05-17 2012-05-17 Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process

Publications (1)

Publication Number Publication Date
TN2013000435A1 true TN2013000435A1 (en) 2015-03-30

Family

ID=54359590

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000435A TN2013000435A1 (en) 2011-12-26 2013-10-24 Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process

Country Status (2)

Country Link
JO (1) JOP20120346B1 (en)
TN (1) TN2013000435A1 (en)

Also Published As

Publication number Publication date
JOP20120346B1 (en) 2023-09-17

Similar Documents

Publication Publication Date Title
WO2013003629A3 (en) Methods and compositions for inhibition of bone resorption
NI201100194A (en) DERIVATIVES OF HAVE [2, 3 - B] PYRIDINE AS INHIBITORS OF VIRAL REPLICATION
TN2015000368A1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
MX2015003653A (en) Benzoimidazole-carboxylic acid amide derivatives as apj receptor modulators.
NZ588830A (en) Inhibitors of protein kinases
BR112015003188A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, COMPOUND USE, AND METHOD FOR TREATMENT OF A RORGAMMAT-MEDIATED DISEASE OR CONDITION IN A PATIENT
MX368504B (en) Amide derivatives and pharmaceutically acceptable salts thereof, preparation method therefor and medicinal application thereof.
MX2013007558A (en) 1,4 oxazines as bace1 and/or bace2 inhibitors.
MX2008013212A (en) 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors.
UA104489C2 (en) Compounds for the treatment of dyslipidemia and related diseases
MX2013010795A (en) 1,3 oxazines as bace1 and/or bace2 inhibitors.
BR112014008045A2 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
EA201391029A1 (en) OXAZIN DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF NEUROLOGICAL DISORDERS
BR112013011634A2 (en) amino alcohol substituted 2,3-dihydroimidazole [1,2-c] quinazoline derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis 2,3-dihydroimidazole [1,2-c] derivatives
MX336051B (en) Diarylacetylene hydrazide containing tyrosine kinase inhibitors.
MX2013007957A (en) 1,4 oxazines as bace1 and/or bace2 inhibitors.
MX2009004908A (en) Chemical compounds.
WO2009125434A3 (en) Oxime derivatives, process for their preparation, pharmaceutical composition containing the same and medicinal use thereof
EA201390984A1 (en) HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA
WO2012064897A3 (en) Bicyclic and tricyclic inhibitors of sumoylation enzymes and methods for their use
UA104988C2 (en) Novel pyrone-indole derivatives and process for their preparation
MX2013014194A (en) Cyclopropyl-fused-1,3-thiazepines as bace 1 and/or bace 2 inhibitors.
MX341577B (en) Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mtor inhibitors.
BR112014028813A2 (en) 5-amino [1,4] thiazines as bace1 inhibitors
GB201302704D0 (en) Therapeutic compounds